Allarity Therapeutics, Inc. (ALLR) Stock Score, Valuation & Financial Research

Allarity Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ALLR

Allarity Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.05. These figures are a research snapshot, not a buy or sell recommendation.

What Allarity Therapeutics, Inc. does

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Allarity Therapeutics is a clinical-stage biopharmaceutical company that focuses on the acquisition and in-licensing of oncology therapeutic candidates. The company utilizes its proprietary Drug Response Predictor (DRP) companion diagnostic technology to identify patients most likely to respond to these treatments, aiming to develop personalized cancer therapies.

Products and services

  • The company's primary product candidate is stenoparib (2X-121), a dual PARP and WNT pathway inhibitor currently in clinical development for advanced ovarian cancer.

Brands and product families

  • Stenoparib — A differentiated, dual PARP and WNT pathway inhibitor for advanced ovarian cancer. Source
  • Drug Response Predictor (DRP) — A proprietary genetic test used to identify patients most likely to benefit from specific cancer drugs. Source

Annual revenue by business

  • License: USD 320,000 · 100.00% calculated revenue share (period 2025-12-31) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Business strengths to evaluate

  • Proprietary Drug Response Predictor (DRP) companion diagnostic technology Source

Business risks and research considerations

  • Substantial doubt regarding the company's ability to continue as a going concern Source
  • Dependence on the successful development and regulatory approval of stenoparib Source

Sources: Company research source · License

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ALLR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.05
Market capitalization:
16.71M (currency not supplied)
Revenue:
USD 345K
Net income:
USD -12.33M
Free cash flow:
USD -14.83M
Cash:
USD 16.98M
Total debt:
USD 22.29M
EPS:
USD -0.78

What stands out

  • Reported year-over-year revenue growth is +7.8%.
  • Free cash flow is USD -14.83M, negative for the stored period.
  • The balance sheet shows USD 16.98M of cash versus USD 22.29M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -4298.0% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -3575.1% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 5.3M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ALLR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can ALLR maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • How long can ALLR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does ALLR's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for ALLR to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ALLR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research ALLR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.